89bio, Inc. (ETNB)
| Market Cap | 2.21B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -450.21M |
| Shares Out | 148.31M |
| EPS (ttm) | -3.41 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 27,292,016 |
| Open | 14.96 |
| Previous Close | 14.96 |
| Day's Range | 14.83 - 15.00 |
| 52-Week Range | 4.16 - 15.06 |
| Beta | 1.27 |
| Analysts | Buy |
| Price Target | 22.31 (+50.03%) |
| Earnings Date | Nov 6, 2025 |
About ETNB
89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. The company was founded in 2018 and is headquartered in San Francisco, California. [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for ETNB stock is "Buy." The 12-month stock price target is $22.31, which is an increase of 50.03% from the latest price.
News
3 Potential Biotech Acquisition Targets
There has been some speculation on Seeking Alpha recently on several biotech/biopharma names that make logical buyout targets. Many firms are on their way to success as standalone entities and have go...
89BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 89bio, Inc. - ETNB
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of 89bio...
Roche To Acquire 89bio For $2.4 Billion In Liver And Cardiometabolic Push
On Thursday, Roche Holdings AG RHHBY agreed to acquire 89bio, Inc. ETNB for $2.4 billion. 89Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of therap...
Top 2 Health Care Stocks That May Keep You Up At Night This Month
As of Sept. 18, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Roche to Buy 89bio for Up to $3.5 Billion
The deal seeks to strengthen the drugmaker's pipeline by adding an experimental drug for an obesity comorbidity.
Roche to acquire liver drug developer 89bio for up to $3.5 billion
Roche said on Thursday it agreed to acquire U.S. biotech firm 89bio ETNB.O for up to $3.5 billion to strengthen its development pipeline on liver and cardiometabolic disease treatments.
89bio, Inc. Announces Agreement to be Acquired by Roche
– 89bio stockholders to receive up to $20.50 per share in cash, comprised of $14.50 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $6.00...
89bio, Inc. (ETNB) Presents At Cantor Global Healthcare Conference 2025 (Transcript)
89bio, Inc. (NASDAQ:ETNB) Cantor Global Healthcare Conference 2025 September 4, 2025 11:30 AM EDT Company Participants Rohan Palekar - CEO & Director Conference Call Participants Steven Seedhouse - C...
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of ...
89bio, Inc. (ETNB) Presents At Citi's Biopharma Back To School Conference Transcript
89bio, Inc. (NASDAQ:ETNB) Citi's Biopharma Back to School Conference September 3, 2025 11:15 AM EDT Company Participants Rohan Palekar - CEO & Director Conference Call Participants Geoffrey Meacham -...
89bio to Participate in Upcoming Investor Conferences
SAN FRANCISCO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the...
89bio: Promising As Pegozafermin Nears Phase 3 Readout
Pegozafermin is ETNB's long-acting FGF21 analog. It's undergoing three Phase 3 trials. Two of those late-stage trials are for MASH (F2-F4), and the third is for severe hypertriglyceridemia. Also, ETNB...
89bio Reports Second Quarter 2025 Financial Results and Corporate Updates
– ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 topline histology data expected in 1H 2027 and in 2028, respectively; each trial designed to support accelerated approval to treat patients with me...
89bio to Participate in Goldman Sachs 46th Annual Global Healthcare Conference
SAN FRANCISCO, June 04, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of i...
89bio Reports First Quarter 2025 Financial Results and Corporate Updates
– Topline histology data from ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials are expected in 1H 2027 and in 2028, respectively; each trial is designed to support accelerated approval to tre...
89bio: A Buy With Strong Market Opportunity In MASH And SHTG
Initiate Buy rating for 89bio, Inc. due to promising lead candidate pegozafermin targeting MASH and SHTG with encouraging Phase 2 data. Pegozafermin may have faster fibrosis improvement and better saf...
89bio to Participate in the Leerink Partners Global Healthcare Conference
SAN FRANCISCO, March 03, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of ...
89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
– ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials in patients with non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic dysfunction-associated steatohepatitis (MASH) continue to ad...
89bio's Pegozafermin Is Now Gaining Momentum
89bio's Pegozafermin Is Now Gaining Momentum
89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded Warrants
SAN FRANCISCO, Jan. 28, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapi...
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
SAN FRANCISCO, Jan. 27, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapi...
89bio: Advancement Of Pegozafermin For SHTG Is Another Path Forward
89bio, Inc. results from the phase 3 ENTRUST study using pegozafermin for the treatment of patients with Severe Hypertriglyceridemia are expected in the 2nd half of 2025. Prior data from the phase 2 E...
89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024
New post-hoc analyses reinforce pegozafermin's potential anti-fibrotic effects and the potential utility of non-invasive tests which correlate to histological endpoints New post-hoc analyses reinforce...
89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants
SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapi...
89bio to Participate in the UBS Global Healthcare Conference
SAN FRANCISCO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of i...